When did Nektar Therapeutics report Q4 2024 earnings?

Nektar Therapeutics (NKTR) reported Q4 2024 earnings on March 12, 2025 before market open.

What were Nektar Therapeutics's Q4 2024 revenue and EPS?

Nektar Therapeutics reported revenue of $29.2M and eps of $-2.25 for Q4 2024.

Did Nektar Therapeutics beat estimates in Q4 2024?

Revenue missed the consensus estimate of $36.7M by $7.5M. EPS missed the consensus estimate of $-1.95 by $0.30.

Where can I find Nektar Therapeutics's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-039389) directly on SEC EDGAR. The filing index links above go to sec.gov.

Nektar Therapeutics NKTR Q4 2024 Annual earnings

Reported March 12, 2025 · Before market open

Revenue$29.2MMiss by $7.5M

EPS-$2.25Miss by $0.30

Revenue estimate$36.7M

EPS estimate-$1.95

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$10.4M

EPS estimate-$1.94

Financials

Q4 2024

Income statement

See full

Revenue$29.2M+22.1%

Gross profit$21.2M+27.7%

Net income-+100%

EPS (diluted)-$2.07-841%

Balance sheet

See full

Cash & equivalents$9.8M-45.0%

Total debt$102.6M-12.9%

Total equity$60.7M-53.6%

Total assets$303.9M-23.7%

Cash flow

See full

Operating cash flow-$46.2M+1.8%

CapEx$459.0K+93.7%

Free cash flow-$46.6M+1.3%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$171.55M+58.9%

Enterprise value$264.29M+27.1%

P/S1.7×+0.5×

Profitability

See full

Gross margin68.8%+6.3pp

Net margin-128.2%-47.1pp

FCF margin-180%-25.0pp

Returns & leverage

See full

Return on equity-131.7%+30.2pp

Debt / equity1.7×+0.8×

Current ratio4.3×-2.2×

Segments

By geography

See full

Non Us$24.3M+23.4%

By product

See full

Non Cash Royalty Revenue Related To Sale Of Future Royalties$16.2M-9.9%

Versus estimates

Revenue

Q1 2026$10.9MBeat by $169.6K Q4 2025$21.8MBeat by $11.6M Q3 2025$11.8MBeat by $1.4M Q2 2025$11.2MBeat by $1.8M Q1 2025$10.5MMiss by $4.9M

Q4 2024$29.2MMiss by $7.5M

Diluted EPS

Q1 2026-$1.82Miss by $0.08 Q4 2025-$1.78Beat by $0.98 Q3 2025-$1.85Beat by $1.00 Q2 2025-$2.95Beat by $0.18 Q1 2025-$3.30Miss by $0.60

Q4 2024-$2.25Miss by $0.30

Ask the moment Nektar Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Nektar Therapeutics report Q4 2024 earnings?: Nektar Therapeutics (NKTR) reported Q4 2024 earnings on March 12, 2025 before market open.
What were Nektar Therapeutics's Q4 2024 revenue and EPS?: Nektar Therapeutics reported revenue of $29.2M and eps of $-2.25 for Q4 2024.
Did Nektar Therapeutics beat estimates in Q4 2024?: Revenue missed the consensus estimate of $36.7M by $7.5M. EPS missed the consensus estimate of $-1.95 by $0.30.
Where can I find Nektar Therapeutics's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-039389) directly on SEC EDGAR. The filing index links above go to sec.gov.